Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with relapsed
or refractory multiple myeloma. Sorafenib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth and by blocking blood flow to the cancer